# Fortrea Holdings Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/Fortrea Holdings Inc.). ## Overview Fortrea Holdings Inc. is a standalone contract research organization created from Labcorp’s drug development business in 2023. It designs and runs clinical development programs for pharmaceutical, biotechnology, and medical device customers, spanning phase I through IV trials, clinical pharmacology, and consulting services. ## Products & services • Phase I-IV clinical trial management • Clinical pharmacology services • Full Service CRO delivery • Functional Service Provider (FSP) models • Hybrid clinical development structures • Consulting and study design support - **Clinical Development Services** (70%) — End-to-end planning, execution, and management of clinical trials across phases I-IV. - **Clinical Pharmacology** (15%) — Specialized early-stage development services supporting dose selection and human pharmacology studies. - **Functional Service Provider (FSP)** (10%) — Dedicated functional outsourcing teams that support specific sponsor functions and workflows. - **Consulting and Advisory** (5%) — Protocol, regulatory, operational, and development strategy support for sponsors. - Phase I-IV clinical trial management - Clinical pharmacology services - Full Service CRO delivery - Functional Service Provider (FSP) models - Hybrid clinical development structures - Consulting and study design support ## Customers Fortrea sells to pharmaceutical, biotechnology, and medical device companies that need outsourced clinical development execution and scientific expertise. Its customer base includes small/emerging biotech sponsors as well as mid-size and large global life sciences companies, with demand driven by the need to run trials faster, across more geographies, and with flexible engagement models. - **Pharmaceutical companies** (primary) — Buy full-service and functional outsourcing for late-stage and global clinical programs to accelerate development. - **Biotechnology companies** (primary) — Buy flexible, high-touch clinical development and pharmacology support to advance pipelines with limited internal infrastructure. - **Medical device companies** (secondary) — Buy clinical trial management and consulting for regulated device development and evidence generation. - **Small and emerging sponsors** (secondary) — Buy scientific, regulatory, and operational support to design studies and execute trials efficiently. - **Large biopharma sponsors** (primary) — Buy scalable global delivery, FSP teams, and hybrid structures for complex multi-country programs. - Pharmaceutical companies outsourcing global trial execution - Biotechnology sponsors needing flexible development support - Medical device companies running regulated clinical studies - Small and emerging biotechs seeking protocol and operational expertise - Large biopharma customers using FSP or hybrid models ## Geography Fortrea operates in approximately 100 countries and says it supports trials in all major pharmaceutical and biotechnology markets. Its workforce is distributed across the Americas, EMEA, and Asia-Pacific, with the largest share in Asia-Pacific, which reflects the global nature of clinical trial site access, patient recruitment, and regulatory execution. - **Americas** (26%) — Employee regional mix disclosed in the report; used as a proxy for operating footprint. - **EMEA** (27%) — Employee regional mix disclosed in the report; used as a proxy for operating footprint. - **Asia-Pacific** (47%) — Employee regional mix disclosed in the report; used as a proxy for operating footprint. - Operations span approximately 100 countries - Trials run across major pharma and biotech markets - Workforce split: 26% Americas, 27% EMEA, 47% Asia-Pacific - Global footprint supports site access and patient recruitment - International mix creates FX and regulatory execution exposure ## Strategy Fortrea’s strategy centers on commercial excellence, operational excellence, and financial excellence, with an emphasis on winning repeat business and expanding its relevance with sponsors. It is also focused on using its global scale and therapeutic expertise to deliver flexible models, strengthen customer relationships, and improve margins through better execution and portfolio mix. - **Grow repeat business and new awards** (short-term) — Clinical CRO revenue depends on winning and retaining sponsor programs, which can be delayed or reduced in scope. - **Improve operational execution and margins** (medium-term) — Better study delivery, site performance, and centralized processing can improve profitability in a service-heavy model. - **Strengthen therapeutic and geographic capabilities** (medium-term) — Broader expertise and global reach help win complex trials and support customer geographic priorities. - Increase reach, relevance, and repeat business - Win more flexible Full Service, FSP, and Hybrid engagements - Deepen expertise across more than 20 therapeutic areas - Use global delivery hubs to improve efficiency and quality - Pursue acquisitions and strategic transactions selectively ## Risks Fortrea’s results depend on sponsor funding, trial award timing, patient recruitment, and investigator availability, so delays or cancellations can quickly affect revenue. Its global operating model also exposes it to foreign exchange, regulatory, geopolitical, and customer concentration risks, while the post-spin structure and acquisition activity add integration and execution risk. - **Delayed or lost net new business awards** [high] — CRO revenue depends on winning sponsor programs; delays or cancellations directly reduce backlog and utilization. - **Patient recruitment and investigator access constraints** [high] — Trials cannot progress without suitable sites and enrolled patients, which can push out timelines and revenue recognition. - **International operating complexity** [medium] — Operating in about 100 countries creates exposure to local regulation, currency movements, and geopolitical disruptions. - **Customer and therapeutic concentration** [medium] — A small number of large sponsors or therapeutic areas can disproportionately affect demand and margins if programs change. - **Integration and acquisition execution** [medium] — Strategic transactions can create disruption, goodwill impairment risk, and operational complexity if not integrated well. - Clinical trial awards can be delayed, reduced, or canceled - Sponsors may lack funding to continue development programs - Patient recruitment and investigator access can constrain delivery - Global operations create FX, regulatory, and geopolitical exposure - Customer and therapeutic concentration can amplify volatility ## Accounting Fortrea’s accounting is shaped by revenue recognition on long-duration service contracts, where timing depends on study progress, pass-through costs, and contract mix. Investors should also watch goodwill impairment, discontinued operations from the Enabling Services sale, and estimates tied to taxes, business combinations, and receivables securitization. - **Revenue recognition on clinical service contracts** — Affects reported growth, margins, and comparability across periods - **Discontinued operations** — Impacts year-over-year comparability and segment analysis - **Goodwill impairment** — Could create material noncash charges if fair value declines - **Receivables securitization** — Influences working capital, cash flow, and leverage optics - Revenue recognition depends on long-term CRO contract progress - Pass-through costs can move revenue and direct costs together - Discontinued operations affect comparability after the Enabling Services sale - Goodwill is tested for impairment and can create large noncash charges - Estimates for taxes, business combinations, and provisions are judgmental --- *Last updated: 2026-04-28T20:08:45.129603+00:00*